Pfizer hopes to raise up to 14,000 million euros for mRNA vaccine in 2030

Pfizer adopts messenger RNA technology (mRNA) to continue growing. The US pharmaceutical company expects sales of its mRNA vaccine portfolio to range between $10 billion and $15 billion (€9.5 billion and €14.2 billion) in 2030.

The pharma It has already projected its revenues to exceed $100,000 million (€94,900 million) in 2022, for the first time in its history, more than double what it was before the pandemic, thanks to demand for the Covid-19 vaccine it developed along with German biotech BioNTech and Paxlovid, its oral antiviral.

Pfizer, like other pharmaceutical developers of Covid-19 vaccines, will see how sales related to this virus decrease in the coming years. In addition, analysts expect revenue for the coronavirus vaccine to decline progressively from 2023, to $6.7 billion (€6.359 million) in 2027, according to the consultancy Refinitiv.

Pfizer will allocate more than 2,500 million dollars to its European manufacturing facilities

In parallel, Pfizer announced last week that it will allocate more than $2.5 billion to its European manufacturing plants located in Belgium and Ireland, where it will begin producing new drugs to replace the benefits gained from the Covid-19 vaccine and expired patents. .

Specific, Pfizer to invest 1,200 million euros in the expansion of its Puurs (Belgium) plant, in addition to investing another 1,200 million dollars in the Dublin plant. Expansion work in Ireland is set to begin in 2024 and not finish until 2027. Once completed, it will create up to 500 jobs and double output, according to a statement released by the company.

In the next year and a half, Pfizer plans to introduce up to 19 new drugs, including treatments for ulcerative colitis and migraine, as well as vaccines against respiratory syncytial virus (RSV). In its domestic market, Pfizer has already announced expansions at plants in Kalamazoo, Michigan, Rocky Mount, North Carolina and Kansas.

For Europe, the US pharmaceutical maker’s investment comes at a time when industries are grappling with rising energy costs, labor shortages, raw material shortages and difficult financial conditions.